Category Archives: Medical Research

What’s New Health Canada?

By Christine Straccini, B.Sc., C.C.R.P., Regulatory Associate II   What’s New in: Therapeutic Products Directorate: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/what-new-drug-products-health-canada.html   Biologics and Genetic Therapies Directorate: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/update-miseajour/index-eng.php Medical Devices: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/what-new.html Natural and Non-prescription Health Products Directorate: https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/what-new.html   Health Canada New Guidance Documents (Drugs … Continue reading

Posted in Cato Research, Drug Development, Health Canada, Medical Research, Regulatory Affairs | Tagged , | Comments Off on What’s New Health Canada?

Time to Approval and the Metrics of Facilitated Regulatory Pathways

By Dr. Jack Snyder, RAC (US, EU, CA, GS), Asst. Managing Director and Clinical Research Physician at Cato Research “Early access pathways” for biomedical product marketing approval have attracted substantial attention recently, as Sarepta Therapeutics’ drug Exondys (eteplirsen) gained accelerated … Continue reading

Posted in Cato Research, Medical Research, Regulatory Affairs, Regulatory Strategy, Regulatory Submissions | Tagged , , | Comments Off on Time to Approval and the Metrics of Facilitated Regulatory Pathways

New FDA Guidances for June 2017

By Michelle Villasmil, Ph.D., RAC (US), Regulatory Scientist at Cato Research FDA draft and final guidances released from CDER, CBER, and CDRH and Manual of Policies and Procedures (MAPPs) of interest released from CDER in June 2017 are posted. In … Continue reading

Posted in Cato Research, FDA, Medical Research, Regulatory Strategy, Regulatory Submissions | Tagged , , | Comments Off on New FDA Guidances for June 2017

New FDA Guidances for May 2017

By Sheila Plant, Ph.D., R.A.C., Assistant Director, Regulatory Strategy, US at Cato Research One revised draft FDA guidance, released from CBER, and two MAPPs, released from CDER, in May 2017, are posted.  In addition, upcoming advisory committee meetings to be … Continue reading

Posted in Drug Development, FDA, Medical Research, Regulatory Submissions | Tagged , , | Comments Off on New FDA Guidances for May 2017

CANCER IMMUNOTHERAPY: A NEW HOPE

By Reshma Jagasia, Ph.D, Scientist at Cato Research The current standard of care for cancer treatment is surgery, chemotherapy, and radiation therapy – a standard that has persisted for decades. These treatments are invasive and not specific, killing healthy cells … Continue reading

Posted in Cato Research, Drug Development, Medical Research | Tagged , , | Comments Off on CANCER IMMUNOTHERAPY: A NEW HOPE